BET bromodomain inhibitor I-BET762 effect on prostate cancer cell lines: dose response
Summary:
Analysis of prostate cancer (PC) cell lines (NCI-H660, VCaP, LNCaP, PC-3) treated with I-BET762 at 0.5uM or 10uM for 24hr. I-BET762 is a highly specific inhibitor of BET (bromodomain and extra-terminal) proteins. Results provide insight into molecular pathways regulated by I-BET762 treatment in PC.
GPL570:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Citation:
Wyce A, Degenhardt Y, Bai Y, Le B et al. Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Oncotarget 2013 Dec;4(12):2419-29. PMID: 24293458
